MX2024002567A - Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. - Google Patents
Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas.Info
- Publication number
- MX2024002567A MX2024002567A MX2024002567A MX2024002567A MX2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- protofibril antibody
- disease
- subject
- subcutaneous formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163260730P | 2021-08-30 | 2021-08-30 | |
| US202263306050P | 2022-02-02 | 2022-02-02 | |
| US202263269389P | 2022-03-15 | 2022-03-15 | |
| US202263269463P | 2022-03-16 | 2022-03-16 | |
| US202263364619P | 2022-05-12 | 2022-05-12 | |
| PCT/US2022/041926 WO2023034230A1 (en) | 2021-08-30 | 2022-08-29 | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002567A true MX2024002567A (es) | 2024-03-20 |
Family
ID=83438517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002567A MX2024002567A (es) | 2021-08-30 | 2022-08-29 | Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240352109A1 (https=) |
| EP (1) | EP4395821A1 (https=) |
| JP (1) | JP2024532438A (https=) |
| KR (1) | KR20240053620A (https=) |
| AU (1) | AU2022338055A1 (https=) |
| CA (1) | CA3230148A1 (https=) |
| MX (1) | MX2024002567A (https=) |
| TW (1) | TW202328178A (https=) |
| WO (1) | WO2023034230A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260022396A (ko) * | 2023-06-09 | 2026-02-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-Aβ 프로토피브릴 항체를 사용한 치료 방법 |
| CN116953261B (zh) * | 2023-08-10 | 2024-09-17 | 浙江格物致知生物科技有限公司 | 一种检测脓毒症的联检试剂盒及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| BR112019008359A2 (pt) * | 2016-10-27 | 2019-10-01 | Eisai R&D Man Co Ltd | método para tratamento da doença de alzheimer, e, composição farmacêutica. |
-
2022
- 2022-08-29 US US18/688,264 patent/US20240352109A1/en active Pending
- 2022-08-29 JP JP2024513446A patent/JP2024532438A/ja active Pending
- 2022-08-29 WO PCT/US2022/041926 patent/WO2023034230A1/en not_active Ceased
- 2022-08-29 KR KR1020247010680A patent/KR20240053620A/ko active Pending
- 2022-08-29 CA CA3230148A patent/CA3230148A1/en active Pending
- 2022-08-29 AU AU2022338055A patent/AU2022338055A1/en active Pending
- 2022-08-29 MX MX2024002567A patent/MX2024002567A/es unknown
- 2022-08-29 EP EP22777104.5A patent/EP4395821A1/en active Pending
- 2022-08-30 TW TW111132756A patent/TW202328178A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202328178A (zh) | 2023-07-16 |
| US20240352109A1 (en) | 2024-10-24 |
| AU2022338055A1 (en) | 2024-02-29 |
| EP4395821A1 (en) | 2024-07-10 |
| JP2024532438A (ja) | 2024-09-05 |
| WO2023034230A1 (en) | 2023-03-09 |
| KR20240053620A (ko) | 2024-04-24 |
| CA3230148A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500006A1 (en) | Methods of treatment and prevention of alzheimer's disease | |
| MX2024002567A (es) | Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. | |
| ATE490470T1 (de) | Therapieverfahren | |
| AU2019302833A8 (en) | Hyaluronic acid filler having high lift capacity and low injection force | |
| MX2020002229A (es) | Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry. | |
| WO2023003518A3 (en) | Methods, compositions and kits for fat remodelling | |
| WO2003039591A3 (de) | Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle | |
| MX2022013427A (es) | Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer. | |
| EP4523750A3 (en) | Methods of reducing cerebrovascular events in patients with fabry disease | |
| WO2022043273A3 (en) | Oral care composition comprising a fructanase | |
| MX2022013923A (es) | Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23. | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| MX2024005197A (es) | Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23. | |
| MX2024005374A (es) | Metodos para tratar la enfermedad de celulas falciformes con voxelotor. | |
| WO2022192639A3 (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| ATE458495T1 (de) | Therapeutische zubereitung für autoimmune erkrankungen | |
| WO2021034616A8 (en) | Methods of treating a subject with a cdc42-specific inhibitor | |
| Patel et al. | Bleomycin induced flagellate pigmentation | |
| AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
| CN204698155U (zh) | 一种保健椅 | |
| Strickler et al. | Modern interpretation of mycotic infections of the feet and hands | |
| RU119603U1 (ru) | Аппарат для шинирования зубов при лечении заболеваний тканей пародонта | |
| Nicholls et al. | Special workshop on repeated and late reactions | |
| Oyapero et al. | Impact of orthodontic treatment on oral health related quality of life at a Tertiary Hospital in Lagos, Nigeria: A pilot study |